Abstract
MCF-7 human breast cancer cells, which are estrogen receptor (ER)-positive and responsive to the mitogenic actions of estrogen, were used to examine the possible association between the growth-inhibitory activity of melatonin and its ability to modulate the estrogen-response pathway. Melatonin at physiologic concentrations (10(-8)-10(-11) M) significantly decreased estrogen binding activity and the expression of immunoreactive ER in a dose-specific and time-dependent manner. However, melatonin did not alter receptor affinity and was unable to compete with estrogen for binding to the ER. Studies in a yeast trancriptional assay system confirmed that melatonin does not directly bind to the ER to modulate ER expression. Thus, it appears that the antimitotic actions of melatonin may be mediated, at least in part, through the suppression of the estrogen-response pathway of MCF-7 cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
